目的探讨癌痛患者采用强阿片类药物镇痛治疗继发便秘的发生率、严重程度及其影响。方法选取2011年10月-2013年2月在江苏省中医院肿瘤内科接受镇痛治疗的107例住院患者，调查强阿片类药物相关性便秘的发生率、严重程度及对生活质量的影响。结果强阿片类药物相关性便秘发生率高达91.6％；在该类便秘各单项评分中，排便费力、排便不尽感位列前2位，积分值远高于其他单项；此类便秘对癌痛患者的生活质量造成严重影响。结论强阿片类药物相关性便秘发生率高、症状严重、持续时间长，是癌痛患者最主要的困扰之一，因此探寻一种有效的特异性针对便秘发生机制、安全简便且患者乐于接受的干预措施迫在眉睫。%Objective To assess the prevalence, severity and impact of opioid-induced constipation (OIC) in cancer patients receiving opioid therapy for chronic pain. Methods Totally 107 cases of patients complaining pain (NRS score for moderate-severe pain), and receiving treatment with strong opioid were surveyed for the occurrence and severity of OIC and its impact on their quality of life. Results The most frequently-seen side effect of strong opioid drugs was constipation (91.6%) and most patients reported that OIC had severely negative impact on their overall quality of life. Conclusion The survey findings confirm that OIC occurs frequently among patients taking opioids for chronic cancer pain, which exerts negative impact on their quality of life. It is necessary to find a safe and acceptable approach specifically targeting the opioid-mediated mechanisms that cause constipation for patients.
展开▼
